Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.

Autoimmune diseases are often treated by glucocorticoids and immunosuppressive drugs that could increase the risk for infection, which in turn deteriorate disease and cause mortality. Low-dose IL-2 (Ld-IL2) therapy emerges as a new treatment for a wide range of autoimmune diseases. To examine its in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pengcheng Zhou, Jiali Chen, Jing He, Ting Zheng, Joseph Yunis, Victor Makota, Yannick O Alexandre, Fang Gong, Xia Zhang, Wuxiang Xie, Yuhui Li, Miao Shao, Yanshan Zhu, Jane E Sinclair, Miao Miao, Yaping Chen, Kirsty R Short, Scott N Mueller, Xiaolin Sun, Di Yu, Zhanguo Li
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Immunologic diseases. Allergy RC581-607 Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/6892f12d515d4852b12e973d2e669c97
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.

Ejemplares similares